Genprex Inc (NASDAQ: GNPX) is likely to have a strong day in the market today, and for good reason. The company announced that it is expanding operations just minutes ago. The news is likely to lead to excitement among investors. Today, we’ll talk about:
- The expanded operations;
- what we’re seeing from GNPX;
- and what we’ll be watching for ahead.
GNPX Expands Operations
As mentioned above, Genprex is likely to have a strong day in the market this morning after announcing that it has expanded operations. In a press release issued early this morning, the company announced that it has established offices in Cambridge, Mass. The new offices in Cambridge were opened with the goal of accelerating clinical development of its lead candidate, Oncoprex™. Oncoprex™ was designed for the treatment of non-small cell lung cancer.
Julien Pham, MD, MPH, newly appointed President and CEO at GNPX, will work from the new offices and oversee the company’s clinical development efforts. He will also work to establish various strategic partnerships as well as provide continued support with regard to the company’s innovation in oncology. Currently, the company is working on its NSCLC development program, including a Phase 2 clinical study with Oncoprex™ in combination with tyrosine kinase inhibitor (TKI, Tarceva) as well as a preclinical program evaluating the anti-tumor activity of Oncoprex™ in combination with immunotherapies. In a statement. Dr. Pham, CEO at GNPX, had the following to offer:
We are excited to establish a footprint in Cambridge, a global center of excellence in life sciences with a highly specialized talent pool… From here, we will advance a number of business activities to support the clinical development of Oncoprex for the treatment of non-small cell lung cancer.
The above statement was followed up by Rodney Varner, Chairman and acting CEO at GNPX. Here’s what he had to offer:
Expanding our clinical operations and accelerating our Oncoprex development program is a key priority.
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on GNPX. In particular, we’re interested in following the company’s operations in Cambridge and elsewhere as it works to bring Oncoprex™ to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!